Economic assessment of clozapine (Leponex®), atypical neuroleptic, in treatment of neuroleptic-resistant schizophrenia;Etude medico-economique du Leponex® (clozapine) au centre hospitalier Charles Perrens de Bordeaux

Encephale

Volumn 24, Issue 4, 1998, Pages 365-377

  Bret, P ^a   Jolivel, C ^a   Bret, M C ^a   Veylit, S ^b   Martin, C ^a   Garcia, P ^a  

^a CENTRE HOSPITALIER CHARLES PERRENS   (France)

^b NONE

Author keywords

Clozapine; Cost effectiveness; Quality of life; Treatment resistant schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGRANULOCYTOSIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; QUALITY OF LIFE; SCHIZOPHRENIA; TREATMENT OUTCOME; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG MONITORING; ECONOMICS; FRANCE; HOSPITAL READMISSION; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COST-BENEFIT ANALYSIS; DRUG MONITORING; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 0031683160     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. BUCHANAN RW. Clozapine : efficacy and safety. Schizophr Bull 1995 ; 21 : 579-91.
2. FITTON A, HEEL RC. Clozapine : a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990 ; 40 : 722-47.
3. GAUSSARES CH. Les indications de la clozapine. Encephale 1992 ; XVIII : 433-6.
4. GRABOT D, MARTIN C, AURIACOMBE M et al. Tableau d'évaluation assistée de la qualité de la vie (TEAQV). Encéphale 1996 ; XXII : 181-5.
5. GURY CH, DECHELETTE N, GAYRAL Ph. Léponex® : l'expérience du pharmacien hospitalier. Encephale 1995 ; XXI (suppl III) : 61-5.
6. GUY W ed : ECDEU Assessment Manual for Psychopharmacology : publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfar 1976 : 217-22.
7. KANE JM. La clozapine dans le traitement de la schizophrénie résistante. Encephale 1991 ; XVII : 159-63.
8. KANE MK. Clinical efficacy of clozapine in treatment-refractory schizophrenia : an overview. Br J Psychiatry 1992 ; 160 : 41-5.
9. KEKS NA. Minimiser les effets indésirables non extrapyramidaux des neuroleptiques. Acta Psychiatr Scand 1996 ; 94 : 18-24.
10. LOMBERTIE ER, SALOME N, VILLEGIER P et al. Arguments pour traiter précocement les schizophrénies résistantes. Encephale 1995 ; XXI (suppl III) : 29-33.
11. MARTIN P. Impacts médico-économiques de la schizophrénie. Encephale 1995 ; XXI (suppl III) : 67-73.
12. MARTIN P. Psychiatrie et qualité de vie : un concept majeur. Schizoscopie janvier 1996 ; 8.
13. MELTZER HY. Treatment of the neuroleptic nonresponsive schizophrenic patient. Schizophr Bull 1992 ; 18 : 515-42.
14. MELTZER HY. Utilisation, multidimensional outcome measures, and risk-benefit considerations for use of clozapine in schizophrenia. Int. Acad Biomed. Drug Res 1993 ; 4 : 103-17.
15. MELTZER HY, COLA PA et al. Cost Effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993 ; 150 : 11, 1630-8.
16. MELTZER HY, COLA PA. The parmacoeconomics of clozapine : a review. J Clin Psychiatry 1994 ; 55 : 161-5.
17. NABER D, HIPPIUS H. The european experience with use of clozapine. Hosp Commun Psychiatry 1990 ; 41 : 886-90.
18. NABER D. A self-rating to measure subjective effect of neuroleptic drugs, relationship to objective psychopathology, quality of live, compliance and other clinical variables. International Clinical Psychopharmacology 1995 ; 10 : 133-8.
19. PERE JJ et al. La clozapine (Léponex®)en France. Données concernant 1 062 patients. Information Psychiatrique 1993 ; 4 : 389-97.
20. REVICKI DA, LUCE B et al. Cost effectiveness of clozapine for treatment-resistant schizophrenics. J Hosp Comm Psych 1991 ; 41 : 850-6.
21. ROUILLON F, DANSETTE GY, LE FLOCH C. Etudes de la prise en charge thérapeutique des schizophrènes et de son coût. Encephale 1994 ; XX : 303-9.
22. SOUETRE E, FRAPPIER J. Economie. Thérapeutique psychiatrique. Herman eds 1995 : 1161-73.
23. TERRA JL. Qualité de vie subjective et santé mentale ; Aspects conceptuels et méthodologiques. Collection Ellipses, Duphar-Upjohn, 1994.